Characteristics |
Complete sample (n=193) |
Albumin<3.3 gr/dl (n=58) |
Albumin>3.3gr/dl (n=135) |
p |
Age |
32,1± 6.24 |
33.7±6.5 |
31.4±6 |
0.021 |
Nuliparous (n=18) |
31.6% |
25.9% |
34.1% |
0.261 |
Twin pregnancy (n=9) |
4.6% |
8.6% |
3% |
0.131 |
In vitro fecundation(n=14) |
7.3% |
18.6% |
5.1% |
0.007 |
Previous PE |
25.0% |
22.4% |
26.1% |
0.586 |
Previous E |
3.1% |
0.0% |
4.3% |
0.173 |
Previous DM |
28.5% |
34.5% |
25.9% |
0.227 |
Type 1 (n=5) |
8.6% |
13.6% |
5.6% |
0.178 |
Type 2 DM (n=13) |
22.4% |
31.8% |
16.7% |
|
Gestational DM (n=40) |
69% |
54.5% |
77.8% |
|
Caesareansection |
48.4% |
56.9% |
44.8% |
0.123 |
Chronic HTN |
39% |
50% |
34.3% |
0.041 |
Gestational HTN |
61% |
50% |
65.7% |
|
Weight gain (Kg) up to 32th week |
10.54±6 |
12±5.8 |
10±6.145 |
0.95 |
APGAR test |
8.63±1.2 |
8.49±1.1 |
8.69±1.3 |
0.04 |
Table 1. Characteristics and background of the population of the study
PE: Preeclampsia. E: Eclampsia. DM: diabetes mellitus. HTNA: hypertension
Characteristics |
Complete sample(n=193) |
Albumin<3.3 gr/dl (n=58) |
Albumin>3.3gr/dl (n=135) |
p |
Hematocrit (mg/dl) |
36.1±2.9 |
36.3±3 |
35.9±2.8 |
0.021 |
Uricacid (mg/dl) |
4.6±13 |
5.0±1.6 |
4.4±1.2 |
0.01 |
SBP (mmHg) |
128±17 |
134±15.4 |
125.6±17 |
0.007 |
DBP (mmHg) |
82.2±12 |
76.4±11.7 |
72.8±11.8 |
0.02 |
Albuminemia (g/dl) |
3.48±0.3 |
3.15±0.2 |
3.6±0.2 |
0.000 |
Proteinuria 24h (g/l) |
0.48±1.09 |
1.0±1.7 |
0.3±0.1 |
0.000 |
BP-loweringtreatment |
56.6% |
67.2% |
54.9% |
0.111 |
Acetylsalicilicacid |
27.2% |
41.4% |
21.1% |
0.04 |
PE* |
29.5% |
43.1% |
23.7% |
0.006 |
Childbirthweight(gr) |
2982±697,7 |
2756±726 |
3076±666 |
0.004 |
Gestational age at delivery (weeks) |
37.4±4 |
36.7±2.9 |
38±2.4 |
0.002 |
Table 2: Analytic parameters, blood pressure, pharmacological treatment and delivery variables
*Includes: PE, HELLP syndrome and Eclampsia. BP: Blood pressure; SBP: Systolic blood pressure; DBP: Diastolic Blood pressure